Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Booming Global Obesity Drug Market

Published by: RNCOS

Published: Dec. 1, 2008 - 80 Pages


Table of Contents


1. Analyst View

2. The Global Obesity Epidemic

2.1 Defining Obesity

2.2 Prevalence of Obesity

2.3 The Cost of Obesity

2.4 Obesity is Linked to Higher Rates of Chronic Conditions

2.5 Obese Spend Significantly Higher on Healthcare

3. Available Weight-loss Techniques & Products

3.1 Weight-loss Surgery

3.2 Liposuction

3.3 Weight-loss Foods & Drinks

3.4 Diet Centres

3.5 Weight-loss Drugs

4. Obesity Drugs Market

4.1 Market Opportunity Assessment

4.2 Key Weight-loss Drugs

4.2.1 Alli

4.2.1.1 Market Performance

4.2.1.2 Critical Success & Risk Factors

4.2.2 Xenical

4.2.2.1 Market Performance

4.2.2.2 Critical Success & Risk Factors

4.2.3 Acomplia

4.2.3.1 Market Performance

4.2.3.2 Critical Success & Risk Factors

4.2.4 Meridia

4.2.4.1 Market Performance

4.2.4.2 Critical Success & Risk Factors

4.3 Weight-loss Drugs under Clinical Trials

5. Obesity in Developed Markets - A Brief Profile

5.1 US

5.2 Japan

5.3 Germany

5.4 UK

5.5 France

5.6 Italy

5.7 Spain

6. Obesity in Emerging Markets - A Brief Profile

6.1 Russia

6.2 India

6.3 Brazil

6.4 China

7. Critical Success Factors

7.1 Expanding Waistlines

7.2 High Unmet Needs

7.3 Self-Consciousness & Fulfillment

7.4 Strong Pipeline

8. Critical Risk Factors

8.1 High Failure Rate

8.2 High Consumer Demand

8.3 Reimbursement Issues

8.4 Side Effects

9. Key Company Profiles

9.1 Abbott Laboratories

9.2 Roche Holding Ltd

9.3 Sanofi-Aventis

9.4 GlaxoSmithKline plc

9.5 Pfizer Inc.


List of Figures:


Figure 2-1: Global - Overweight & Obese Adults* (in Million), 2005, 2007 & 2012

Figure 2-2: Global - Proportion of Normal, Overweight & Obese Adults in Global Population (%), 2005, 2007 & 2012

Figure 2-3: Relation between Obesity & Increasing Chronic Conditions (%)

Figure 2-4: Odd Ratios for Selected Physical Conditions Related to Obesity, Aging, Smoking & Drinking

Figure 2-5: Relation between Obesity & Increasing Healthcare Cost (%)

Figure 3-1: US - Bariatric Surgeries Preformed (in Number), 2003 & 2007

Figure 4-1: Global - Obesity Drugs Market* (in Million US$), 2005-2007 & 2012F

Figure 4-2: Global - Obesity Drugs Market by Weight-loss Drugs (%), 2007

Figure 4-3: Global - Alli Revenues (in Million US$), 2007 & 2012F

Figure 4-4: Global - Xenical Revenues (in Million CHF), 2005, 2007 & 2012F

Figure 4-5: Global - Acomplia Revenues (in Million Euro), 2006-Q3 2008

Figure 4-6: Global - Meridia Revenues (in Million US$), 2006, 2007 & 2012F

Figure 5-1: US - Obesity Drugs Market (in Million US$) 2007 & 2012F

Figure 5-2: US - Weight-loss Market (in Billion US$), 2006, 2007E & 2012F

Figure 5-3: UK - Prescriptions Dispensed for Obesity Drugs (in Number), 1999 & 2006

Figure 6-1: Russia - Obesity Drugs Market by Weight-loss Drugs (%), 2006

Figure 6-2: Russia - Slimming Food Supplements Market by Product (%), 2006

Figure 6-3: India - Obesity Drugs Market (in Million US$), 2005 & 2006

Figure 7-1: Comparison of Safety & Efficacy of Obesity Management Approaches


List of Tables:


Table 2-1: Classification of Normal, Overweight & Obese on the Basis of BMI

Table 3-1: US - Liposuction Statistics (2007)

Table 4-1: Alli - Success & Risk Factor Analysis

Table 4-2: Xenical - Success & Risk Factor Analysis

Table 4-3: Acomplia - Success & Risk Factor Analysis

Table 4-4: Meridia - Success & Risk Factor Analysis

Table 4-5: Obesity Drugs in Phase-III Clinical Trials

Table 4-6: Obesity Drugs in Phase-II Clinical Trials

Table 4-7: Obesity Drugs in Phase-I Clinical Trials

Table 5-1: US - Overweight & Obesity Statistics (1990, 2000, 2006, 2007E & 2012F)

Table 5-2: Japan - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 5-3: Germany - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 5-4: UK - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 5-5: France - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 5-6: Italy - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 5-7: Spain - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 6-1: Russia - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 6-2: India - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 6-3: Brazil - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 6-4: China - Prevalence of Overweight & Obesity in Males & Females (%), 2005 & 2015F

Table 8-1: Potential Side-effects from Commonly Used Obesity Drugs

Table 9-1: Abbott Laboratories - Strengths & Weaknesses

Table 9-2: Roche Holding Ltd - Strengths & Weaknesses

Table 9-3: Sanofi-Aventis - Strengths & Weaknesses

Table 9-4: GlaxoSmithKline plc - Strengths & Weaknesses

Table 9-5: Pfizer Inc. - Strengths & Weaknesses

Abstract

“Booming Global Obesity Drug Market”, our latest research on the obesity market, states that the prevalence of obesity is increasing globally at alarming rates. Obesity drugs market has shown a radical growth in recent times but in contrast, the market for weight loss drugs has failed to match this growth. By 2012, it’s expected that more than two billion people will be overweight and 600 Million will be obese, representing immense opportunities for both the markets.

The market for weight loss drugs is characterized by numerous failures. A number of drugs have failed to get approval, some have been recalled, and those that have entered the market either suffer from serious side effects or have just failed to give the desired weight loss results consumers expected from them. Refusal of healthcare authorities to grant reimbursement to these drugs has also impeded the growth. One of the most recent examples can be taken from Sanofi’s Acomplia; the drug was hailed as multibillion blockbuster before it was launched. But Acomplia, like most of its predecessors, failed to have a sufficient benefit to risk ratio and was taken off the market just two and a half years after its launch.

The future of the obesity drugs market, however, may not be so gloomy. This is because the market has high unmet demand, and any drug that manages to provide a high benefit to risk ratio can easily achieve blockbuster status. Moreover, despite some of its recent failures, the obesity drugs pipeline is rich and a large number of drugs are in phase-III and late phase-II trials. If some of these drugs manage to reach the market and posses a strong efficacy and safety profile, they can quickly become billion-dollar blockbusters.

Country-wise, the US is presently the biggest market for weight loss drugs with around 68% of its population either overweight or obese. The US is followed by the UK and other European countries. In future, emerging economies such as China, Russia, India and Brazil are also expected to become a huge market for weight loss products. With China’s obesity and overweight levels touching 665-670 Million in 2015, the country will emerge as the most potential weight loss market.

Our report gives an extensive and objective analysis on the global market for obesity drugs. It identifies the past and current performance of the market, and outlines the future trends shaping the industry. It comprehensively assesses the performance of drugs, both in the market and in developing stage. Based on various present and future indicators, the report evaluates future outlook and performance of key products in the industry. The research can thus give valuable information to manufacturers/investors planning to foray into the obesity drugs market.

Our report provides forecast on
  • Global obesity market
  • Xenical revenue
  • Meridia revenue
  • Alli revenue
  • Global prevalence of obesity
  • Prevalence of obesity in major developed and emerging markets
Profiling on Key Players

This section gives business overview of the key players, including Roche Holding Ltd, Sanofi-Aventis and Pfizer, who are operating in the global obesity drugs market. It also highlights the strengths and weaknesses of each company.

Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report
Price and Delivery Options
Search Inside Report


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009